FDA Modifies Indications of Pembrolizumab, AtezolizumabBy mrvta - July 9, 2018Facebook Twitter Linkedin Email Print The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are not eligible for platinum-based chemotherapy.
